NervGen Pharma Corp. Common stock
NGEN | NASDAQ
$1.37
-$0.07 (-4.86%)
At close: Oct 30, 2026, 4:00 PM ET
$1.55
+$0.18 (+13.14%)
Pre-market:
Nov 2, 2026, 4:01 AM ET
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 | FY 2022 Dec 31, 2022 | FY 2021 Dec 31, 2021 | FY 2020 Dec 31, 2020 |
|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | 83.74K | 145.01K | 114.1K | 42.95K | 39.73K |
Gross Profit | n/a | -83.74K | -145.01K | -114.1K | -42.95K | -39.73K |
Operating Income | -25.08M | -24.92M | -17.78M | -22.82M | -12.91M | -11.22M |
Interest Income | 333.42K | 812.07K | 550.12K | 199.62K | 29.64K | 18.89K |
Pretax Income | -44.12M | -23.99M | -22.38M | -20.54M | -12.82M | -11.21M |
Net Income | -44.12M | -23.99M | -22.38M | -20.54M | -12.82M | -11.21M |
Selling & General & Admin | 11.17M | 9.17M | 9.63M | 6.28M | 5.98M | 5.04M |
Research & Development | 13.91M | 15.66M | 8M | 16.43M | 6.88M | 6.14M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 25.08M | 24.83M | 17.63M | 22.71M | 12.87M | 11.18M |
Interest Expense | n/a | n/a | n/a | 510.07K | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 25.08M | 24.92M | 17.78M | 22.82M | 12.91M | 11.22M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 72.33M | 67.32M | 59.29M | 52.65M | 39.29M | 32.11M |
Shares Outstanding (Diluted) | 72.33M | 67.32M | 59.29M | 52.65M | 39.29M | 32.11M |
EPS (Basic) | -0.61 | -0.36 | -0.37 | -0.39 | -0.33 | -0.34 |
EPS (Diluted) | -0.61 | -0.36 | -0.37 | -0.39 | -0.33 | -0.34 |
EBITDA | -5.65M | -23.91M | -22.24M | -19.92M | -12.78M | -11.17M |
EBIT | -5.71M | -23.99M | -22.38M | -20.03M | -12.82M | -11.21M |
Depreciation & Amortization | 55.8K | 83.74K | 145.01K | 114.1K | 42.95K | 39.73K |
Add to Watchlist
Select watchlists to add or remove NGEN